System of lenses for presbyopes with different eye vision

FIELD: medicine.

SUBSTANCE: set of lenses for patients with presbyopia with different eyesight contains: a selection guide with lens design and additional optical power options and a group of lenses having a variety of designs, each having its own refractive power. In such a system, for each lens design and selection specified in the guide, the visual inconsistency of is within the range specified by unequations >0.2*add. power + 0.2 and <0.7*add. power + 0.5. The value of additional power is less than or equal to 1. A method for creation of a set of contact lenses for patients with presbyopia with different eye vision contains the following stages: creation of a guide for selection with lenses optical power and required additional power; establishment of an evaluation function, which provides measurement of binocular vision at a great distance, middle distance and near in the entire range of additional power specified in the guide; and application of optimisation to establish lens design and modification of the selection guide that reduce the overall assessment function of the system.

EFFECT: application of this group will improve visual effectiveness.

13 cl, 16 dwg, 6 tbl, 4 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: implant layers are presented in the form of congruent ellipsoids of rotation consisting of polymers and/or copolymers of glycosaminoglycans, lactic acid and polyvinylpyrrolidone; all drug-saturated layers are alternated with drug-unsaturated layers, while solubility of each implant layer is provided by hydrolysis of cross linkage and directly proportional to their number.

EFFECT: achieving and maintaining the required drug concentration in the vitreal cavity for the required period of time, no risk of damaging the intraocular structures with high-concentrated drug substances, reducing the intraoperative injury.

2 cl

FIELD: medicine.

SUBSTANCE: implant for the revascularisation of a posterior pole of eyeball is a porous composite of polyethylene tetraphthalate or polycarbonate track-etched membranes with the improved medical-biological properties. Improving the medical-biological properties of the track-etched membranes requires additional plasma processing of cyclohexane.

EFFECT: using the given implant enables improving the trophism and mechanical properties of the sclera in the posterior pole of the eyeball that prevents an optic nerve disorder.

2 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention can be used for performing a goniopuncture of trabeculo-Descemet's membrane following a non-penetrating deep sclerectomy (NPDS) if observing disturbed transparency of a cornea or fluid flow of an anterior chamber. The trabeculo-Descemet's membrane is micro-perforated from an angle of the anterior chamber within a projection of a postoperative intrascleral cavity by means of a non-traumatic boomerang needle 10-0, needle bend 3/8. The needle is pricked into the cornea at 3-3.5 mm from a limb with its distal end delivered towards an opened portion of the Descemet's membrane. A needle tip is brought through the cornea and further and advanced along a trajectory aligned with its flexion; the needle tip perforates the trabeculo-Descemet's membrane.

EFFECT: method enables achieving the stable normalisation of intraocular pressure following a minimum surgical intervention.

1 ex

FIELD: medicine.

SUBSTANCE: nasolachrymal canal is intubated with a perforated silicone tube with a hole diameter 23G; the holes are staggered at 3 or 4 mm from each other. A distal end of the tube is blocked, whereas a proximal one is fixed in a projection of semilunar fold. A medicinal gel is introduced into a tube lumen every 7 days during the whole period of intubation - up to 3 months.

EFFECT: method provides the prolonged dilation of the lumen of the lachrymal passages and a possibility of the dosed administration of a medicinal preparation around a silicone frame for a long period of time and the recovery of the lachrymal passages patency, and the prevention of recurrent stricture formation, and the lower injury rate.

2 ex

FIELD: medicine.

SUBSTANCE: anaesthetising patients with chronic pain syndrome undergoing a cyclophotocoagulation surgery involves the intravenous administration of the hormonal preparation dexamethasone in a dose of no more than 8 mg followed by the anxiolytic droperidol in a dose of no more than 2.5 mg 5 minutes prior to the operation before the peribulbar anaesthesia. A peripheral block in the form of the peribulbar anaesthesia involving administration of no more than 6 ml of a local anaesthetic follows. At the moment the surgical procedure starts, benzodiazepin, e.g. diazepam, is administered in a dose of no more than 5 mg.

EFFECT: achieving adequate anaesthesia in the given category of patients by blocking all the links of a pathological pain chain.

1 ex

FIELD: medicine.

SUBSTANCE: method involves removing an epithelial layer, exposing a cornea by saturating it through multiple instillations of 0.1% riboflavin followed by the ultraviolet exposure. After the epithelial layer has been removed, a ring made of an ultraviolet-protected contact lens is applied on a surface of the eyeball perilimbally. An outer diameter of the ring covers the limb by no more than 2 mm, whereas an inner diameter of the ring is equal to a basic diameter of the keratoconus. The whole duration of the ultraviolet exposure involves additional instillations of riboflavin on the cornea every 3-4 minutes. The exposure is characterised by wavelength 365 nm, power 3.0 mWt/cm2 at 50 mm for 30 minutes with the ring to be removed after the exposure is completed.

EFFECT: method is easy to implement, involves no difficulties for specialists, providing higher clinical effectiveness by limiting the ultraviolet exposure area, preventing the ultraviolet involvement of the limb and reducing a risk of postoperative complications.

1 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to surgery. A surgical console comprises a pneumatically operated valve; the first port and the second port connected to the valve configured to feed compressed gas into each of the first port and the second port alternatively; a pressure sensor connected to the ports; and a controller connected to the valve and pressure sensor. The controller is configured to control the time of open and closed state of a valve passage in accordance with the working cycle of the valve. The time of the open state of the valve corresponds to the first port open time, whereas the time of the close state of the valve corresponds to the first port close time. The controller is also configured to receive a measured port pressure differential and to calculate the port pressure differential in accordance with the pressure sensor data, and to modify the working cycle of the valve depending on the difference of the measured or calculated pressure differential and the desired mean pressure differential for reducing a difference of these values. What is disclosed is a method for the valve adjustment.

EFFECT: maintaining the pressure required for the correct operation of the attached instruments.

19 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: conjunctival flap is formed. Surface sclera and deep triangular flaps are formed with base to limbus with exposure of ciliary body. 2 scleral channels are formed on each side of triangular flap, perpendicular to them. External end of sclera channels must project beyond bed of surface sclera flap. Two collagen drainages "xenoplast" 0.8-1.2 mm thick, 1.0-1.5 mm wide, 4.0-5.0 mm long, are sutured to formed sclera bed. Length of collagen drainages must not exceed length of sclera flap. Anterior eye chamber is opened by cut along limbus. Iridectomy is performed. Anterior chamber is fully filled with viscoelastic. Ends of two drainages are introduced into anterior chamber, with formation of window in trabeculo-Descemet's membrane. Root of iris must not overlap ends of drainages. Surface sclera flap is laid into place and fixed with sutures.

EFFECT: method provides activation of intraocular fluid outflow for long term, formation of flat spilled filtration pillow with strong wall, prevention of scarring of created pathways for outflow without application of antimethabolites due to formation of sclera channels, external end of which lies beyond bed of surface sclera flap, application of collagen drainages without their overlapping by iris root and length which does not exceed length of scleral flap.

4 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and can be used in treating amblyopia in children. One 10-minute procedure involves alternating 1-2-minute exposure to green-range laser speckle structures at wavelength 0.5-0.65 mcm and red-range laser speckle structures at wavelength 0.63-0.7 mcm. Laser fluence is (4-8)10-5 W/cm2. That is combined with autoscan exposure to a travelling magnetic field from temporal lobes to an occipital region by bitemporal method at a scan frequency of 90-180 Hz. A field density is 30-45 mT. The procedures are daily for 10 days.

EFFECT: method provides stimulating the maximum count of retinal cells responsible for colour vision, prevents the eye tissue adaptation to laser light, optimises delivering visual pulses along the visual pathway to the visual cortex.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used for the removal of silicone oil from the anterior eye chamber. 2 paracenteses are performed. An irrigation cannula of the phacoemulsifier is introduced into one of the paracenteses. Supply of physiological solution is realised. Removal of silicone takes place passively (by gravity) through the second paracentesis.

EFFECT: method makes it possible to remove silicone oil form the anterior eye chamber in a reliable way with low trauma due to the uniform, without differences in pressure, supply of physiological solution by means of an irrigation system and passive removal of silicone oil through the paracentesis.

1 ex

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing hypotensive means by means of instillations. Eye drops of emoxipin are instilled 20-30 min later twice a day during 4-8 weeks. The treatment course is repeated in 2-3 months.

EFFECT: improved vision function; normalized hemodynamic values.

1 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: one should apply an autohemocomponent preparation being supernatant liquid of patient's autoblood at increased serotonin content obtained due to irreversible thrombocytic aggregation due to the impact of 0.5 mg ATP per 1.0 ml plasma followed by a 30-min-long centrifuging at the rate of 1000, 2000 and 3000 rot./min for 20, 7 and 3 min, correspondingly. In case of no exudative phenomena on patient's eye bottom the obtained preparation should introduced at the quantity of 7-10 ml once in 48 h for 1 mo (totally, 15 injections). In case of exudative-hemorrhagic phenomena it should be introduced parabulbarly at the volume of 0.5 ml and parenterally - 7.0-10.0 ml once in 48 h for 1 mo per 15 injections, correspondingly. The preparation enables to improve visual functions due to decreased tissue hypoxia and normalization of microcirculation in visual analyzer.

EFFECT: higher efficiency of therapy.

2 cl, 7 dwg, 2 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: one should apply an autohemocomponent preparation being supernatant liquid of patient's autoblood at increased serotonin content obtained due to irreversible thrombocytic aggregation due to simultaneous impact of 0.5 mg ATP per 1.0 ml plasma followed by a 30-min-long centrifuging at the rate of 1000, 2000 and 3000 rot./min for 20, 7 and 3 min, correspondingly. Preparation should introduced parabulbarly at the volume of 0.5-1.0 ml, parenterally - 7.0-10.0 ml once daily at 20 injections for 1 mo. The method enables to increase visual functions due to normalization of functional activity of photoreceptors and neurons of internal layer in retinal peripheral departments.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves administering vision training exercises by carrying out duplicated test object images fusion. The test objects are illuminated with laser radiation. Continuous observation of Polaroid anaglyphs with speckle structure of laser radiation corresponding to the right and left eye. Alternating accommodation loading is carried out under eye retina stimulation conditions with speckle structure of laser radiation.

EFFECT: enhanced strength of monocular image fusion.

FIELD: medicine, in particular ophthalmology.

SUBSTANCE: claimed composition contains (mass %): antiviral drug 0.001-5; vegetable and/or animal phospholipids 0.001-2; sodium chloride 0.8-0.9; sodium hydrophosphate 0.001-0.2; sodium dihydrophosphate 0.001-0.2; and balance: distilled water.

EFFECT: composition with prolonged and effective action.

3 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: one should make a blind circular incision for the preset depth along the border of recipient's biolense bottom, form a peripheral "pouch" in corneal stroma along external edge of circular incision of 0.5-1.0 mm width, deepithelize patient's cornea within biolense's bottom, put an optically negative biolense manufactured out of donor's cornea onto this bottom to fix it with interrupted sutures and reset biolense's edges into stromal "pouch". During applying fixing sutures one should simultaneously carry out compression of recipient's ectopic cornea through a biolense. The method enables to flatten and decrease refracting corneal power that leads to corneal spreading without any deformation and development of folds in Descemet's membrane.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with decreasing intraocular pressure during carrying out operative interferences in case of cataract and glaucoma. One should introduce 5%-pentamine solution together with anesthetic solution into sub-Tenon's space at the quantity of 0.1-0.4 ml and 1.0-1.5 ml, correspondingly. The method enables to achieve considerable decrease of intraocular pressure and, thus, provide decreased quantity of such complications, as prolapse of vitreous body, iris and corneal endothelium traumatization.

EFFECT: higher efficiency.

4 ex

FIELD: medicine.

SUBSTANCE: method involves producing ophthalmoscopic tumor image and visually estimating its pigmentation. Digital computer-assisted analysis of tumor image color parameters is carried out by applying Adobe Photoshop software. Digital 0 code is assigned to absolutely black color and digital code of 765 is assigned to absolutely white color. Transpupillary diode laser thermotherapy is started with color code of 153 to 289 beginning from power density of 4.2 W/cm2. Color code being of 290 to 503, the treatment begins with 7.8 W/cm2. Color code being of 504 to 635, the treatment begins with 11.4 W/cm2.

EFFECT: enhanced effectiveness of treatment owing to initial power density being accurately selected.

FIELD: medicine.

SUBSTANCE: method involves determining arrangement of ciliary body and its appendices relative to line passing through limbus and anterior chamber angle and perpendicular to iris plane. The ciliary body and its appendices taking frontal position relative to the line, intraocular lens implantation through corneal tunneling incision is considered to be indicated. The ciliary body and its appendices taking median or posterior position relative to the line, intraocular lens implantation through corneoscleral tunneling incision is to be indicated.

EFFECT: reduced risk of postoperative complications.

Up!